Home Cart Sign in  
Chemical Structure| 274901-16-5 Chemical Structure| 274901-16-5

Structure of Vildagliptin
CAS No.: 274901-16-5

Chemical Structure| 274901-16-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Vildagliptin is an inhibitor of DPP-4 with IC50 of 2.3 nM that is used in the treatment of type 2 diabetes mellitus.

Synonyms: LAF237; NVP-LAF 237; Zomelis

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Vildagliptin

CAS No. :274901-16-5
Formula : C17H25N3O2
M.W : 303.40
SMILES Code : O[C@@]1(C2)C[C@H]3C[C@H](C[C@]2(NCC(N4[C@H](C#N)CCC4)=O)C3)C1
Synonyms :
LAF237; NVP-LAF 237; Zomelis
MDL No. :MFCD08275142

Safety of Vildagliptin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human umbilical vein endothelial cells (HUVECs) High dose group: 240 mg/40 mg (PLGA/vildagliptin, w/w); Low dose group: 260 mg/20 mg (PLGA/vildagliptin, w/w) 14 days To evaluate the effect of vildagliptin on HUVECs migration. Results showed that both high and low doses of vildagliptin significantly promoted HUVECs migration (high dose group: 224±33%; low dose group: 161±34%). PMC6751553
3T3-L1 adipocytes 1 nM, 10 nM, 100 nM 24 hours To assess the effect of vildagliptin and GLP-1 on adiponectin expression in 3T3-L1 adipocytes. Results showed that GLP-1 significantly increased adiponectin mRNA expression, while vildagliptin had no significant effect. PMC4175356
Human leukemia HL-60 cells 1 μM, 10 μM, 100 μM 24 hours To investigate the effect of vildagliptin on S100A8, S100A9, and TNF-α mRNA expression. Results showed that vildagliptin significantly induced the mRNA expression of S100A8 and S100A9 but had no significant effect on TNF-α mRNA expression. PMC5069476
Human hepatoma HepG2 cells 1 μM, 10 μM, 100 μM 24 hours To investigate the effect of vildagliptin on S100A9 and TNF-α mRNA expression. Results showed that vildagliptin increased the mRNA expression levels of S100A9 and TNF-α in a concentration-dependent manner. PMC5069476
Rat cardiac myoblast H9c2 cells 30μM 48 hours To evaluate the effect of vildagliptin on autophagy in H9c2 cells under high glucose conditions. Results showed that vildagliptin restored autophagy levels, reduced P62 expression, and increased LC3 aggregation. PMC8013777
Rat cardiac myoblast H9c2 cells 30 μM 48 hours To evaluate the effect of vildagliptin on autophagy in H9c2 cells under high glucose conditions. Results showed that vildagliptin restored autophagy levels, reduced P62 expression, and increased LC3 aggregation. PMC8013777
Human umbilical vein endothelial cells (HUVECs) 1.0 μM 48 hours VLD significantly reduced mtROS production and mitochondrial DNA damage, enhanced ATP synthesis, reduced the expression of Drp1 and Fis1, blocked Drp1 translocation into mitochondria, and blunted mitochondrial fragmentation induced by hyperglycemia. PMC6349192
Human umbilical vein endothelial cells (HUVECs) 1 nM, 5 nM, 10 nM 6 hours To assess the effect of vildagliptin and/or GLP-1 on the formation of vascular-like structures by HUVECs on a Matrigel matrix. Results showed that treatment with vildagliptin or GLP-1 promoted the formation of vascular-like tubes, with GLP-1 being more effective. PMC4175356
Human lung microvascular endothelial cells (HMVEC-L) 10 nM 96 hours To evaluate the inhibitory effect of vildagliptin on LPS-induced endothelial-to-mesenchymal transition (EndMT) in the absence of immune cells or GLP-1. Results showed that vildagliptin significantly attenuated EndMT. PMC5644255

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL6/J mice Hind limb ischemia model Drinking water 0.6 mg/ml/day/mouse Administration started 3 days before surgery and continued for up to 3 weeks after surgery. To assess the effect of vildagliptin on ischemia-induced revascularization. Results showed that vildagliptin treatment significantly enhanced blood flow recovery and capillary density in the ischemic limbs of wild-type mice, but not in eNOS-deficient mice. PMC4175356
C57BL/6 mice Systemic endotoxemic lung injury model Intraperitoneal injection 10 mg/kg Once daily for 14 consecutive days To evaluate the ameliorative effect of vildagliptin on pulmonary fibrosis in a systemic endotoxemic lung injury model. Results showed that vildagliptin ameliorated pulmonary fibrosis by downregulating EndMT. PMC5644255
Mice C57BL/6NCrSlc mice Oral 1000 mg/kg Single dose, sampled after 24 hours To investigate the effect of vildagliptin on hepatic gene expression in mice. Results showed that vildagliptin significantly induced the mRNA expression of S100a8 and S100a9. PMC5069476
Mice Type 2 diabetic mouse model Oral gavage 15.17 mg/kg/day Once daily for 10 weeks To evaluate the effect of vildagliptin on cardiac function and autophagy in diabetic cardiomyopathy mice. Results showed that vildagliptin improved cardiac function, restored autophagy levels, and alleviated fibrosis. PMC8013777
Mice BKS.Cg-Dock7m+/+Leprdb/Nju (db/db) mice Oral 35 mg/kg Once daily for 6 weeks VLD significantly reduced blood glucose and serum triglyceride levels, decreased vascular ROS and mtROS production, increased NO generation, and inhibited the expression of Drp1 and Fis1, improving mitochondrial dysfunction in diabetic mice. PMC6349192
Sprague-Dawley rats Diabetic wound model Topical administration 40 mg vildagliptin with 240 mg PLGA 14 days Evaluate the effect of vildagliptin/PLGA nanofibrous membranes on diabetic wound healing, results showed accelerated wound closure and increased angiogenesis PMC9696371
Wistar albino rats 3-nitropropionic acid (3NP)-induced Huntington's disease model Oral 5 mg/kg/day Once daily for 14 days Vildagliptin attenuated Huntington's disease through activation of GLP-1 receptor/PI3K/Akt/BDNF pathway, improving cognitive and motor deficits, restoring mitochondrial function and oxidative stress balance, and modulating neurotransmitter levels. PMC7007456
Asians Type 2 diabetes patients Oral 50 mg bid Twice daily for 24 weeks To assess the efficacy and safety of vildagliptin as add-on therapy to insulin in Asian patients with type 2 diabetes mellitus. Results showed that vildagliptin significantly reduced HbA1c without increasing the risk of hypoglycemia or weight gain. PMC3746088
C57BL/6 mice MPTP-induced Parkinson’s disease model Oral 50 mg/kg Once per day for seven days To evaluate the protective effects of vildagliptin against MPTP-induced motor dysfunction, results showed that vildagliptin significantly improved MPTP-induced motor coordination deficits and motor learning impairment. PMC8877991
Mice KK-Ay diabetic mice and C57BL/6JJcl (B6) control mice Oral 50 mg/kg/day Once daily for 4 weeks Vildagliptin increases βcell mass by not only directly affecting cell kinetics but also by indirectly reducing cell apoptosis, oxidative stress and endoplasmic reticulum stress in diabetic mice. PMC3558804
New Zealand white rabbits Diabetic model (induced by intravenous injection of alloxan) Local release (via stent implantation) High dose group: 240 mg/40 mg (PLGA/vildagliptin, w/w); Low dose group: 260 mg/20 mg (PLGA/vildagliptin, w/w) Single implantation, lasting for 8 weeks To evaluate the effect of vildagliptin-eluting stents on re-endothelialization and neointimal formation in diabetic rabbits. Results showed that both high and low doses of vildagliptin significantly promoted re-endothelialization (high dose group: 98.4±1.0%; low dose group: 95.4±1.1%) and reduced neointimal formation. PMC6751553

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01582308 Type 2 Diabetes Mellitus Phase 1 Completed - -
NCT01582308 - Completed - -
NCT00099931 Diabetes Mellitus, Type 2 Phase 3 Completed - Germany ... More >> Novartis Investigative Site Investigative Sites, Germany Less <<
NCT00396227 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Less <<
NCT00351832 Diabetes Mellitus, Type 2 PHASE3 COMPLETED - Novartis Pharmaceuticals, Toky... More >>o, Japan Less <<
NCT00099905 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Less <<
NCT00101673 Diabetes Mellitus, Type 2 Phase 3 Completed - Switzerland ... More >> Novartis Pharmaceuticals Basel, Switzerland Less <<
NCT00138567 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Investigative Site East Hanover, New Jersey, United States, 07936 Germany Novartis Investigative site Investigative Centers, Germany Less <<
NCT00237237 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Germany Investigative Centers Nurnberg, Germany Less <<
NCT00494884 Diabetes Mellitus, Type 2 Phase 3 Completed - Germany ... More >> Novartis Investigative Site Bochum, Germany Less <<
NCT00099944 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Less <<
NCT00120536 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Less <<
NCT00138619 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Germany Investigative Centers, Germany Less <<
NCT00102388 Diabetes Mellitus, Type 2 Phase 3 Completed - Germany ... More >> Novartis Investigative Site Investigative Centers, Germany Switzerland Novartis Pharmaceuticals Basel, Switzerland Less <<
NCT01757587 Type 2 Diabetes Phase 4 Completed - France ... More >> CH Sud Francilien Evry, France, 91000 Less <<
NCT00325429 Diabetes Mellitus, Type 2 PHASE3 COMPLETED - Novartis Pharmaceuticals, Toky... More >>o, Japan Less <<
NCT00260156 Diabetes Mellitus, Type 2 Phase 3 Completed - Switzerland ... More >> Novartis Pharmaceuticals Basel, Switzerland Less <<
NCT00138593 Diabetes Mellitus, Type 2 Phase 3 Completed - Switzerland ... More >> Novartis Pharmaceuticals Basel, Switzerland Less <<
NCT01867502 Diabetes Mellitus, Type 2 ... More >> Hypoglycemic Agents Diabetic Blood Glucose Monitoring Exercise Less << Phase 4 Unknown August 2015 Brazil ... More >> Hospital de Clínicas de Porto Alegre Porto Alegre Recruiting Porto Alegre, Rio Grande do Sul, Brazil, 90035-903 Contact: Aline Fofonka, MSc    55-5192339191    alinefofonka@hotmail.com    Principal Investigator: Beatriz D Schaan, PhD Less <<
NCT00419887 Healthy Phase 1 Completed - China ... More >> Novartis Beijing, China Less <<
NCT01122641 Insulin Resistance ... More >> Microvascular Disease Less << Phase 3 Completed - United Kingdom ... More >> Diabetes and Vascular Research Department Exeter, Devon, United Kingdom, EX2 5AX Less <<
NCT00351507 Diabetes Mellitus, Type 2 PHASE3 COMPLETED 2025-02-06 Mayo Clinic, Rochester, Minnes... More >>ota, 55905, United States Less <<
NCT00770081 Diabetes Mellitus, Type 2 ... More >> Renal Insufficiency Less << Phase 3 Completed - -
NCT00728351 Diabetes Mellitus, Type 2 Phase 3 Completed - -
NCT00975065 Type 2 Diabetes Mellitus Phase 4 Completed - Korea, Republic of ... More >> Handok Pharmaceuticals Seoul, Korea, Republic of Less <<
NCT00468039 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, Texas ... More >> Diabetes and Glandular Disease Research Associates San Antonio, Texas, United States, 78229 Less <<
NCT00821977 Diabetes Mellitus, Type 2 Phase 2 Phase 3 Completed - -
NCT00646542 Diabetes Mellitus, Type 2 Phase 3 Completed - Argentina ... More >> Buenos Aires, Argentina Australia Heidelberg Heights, Australia Canada Winnipeg, Canada Costa Rica Cartago, Costa Rica Finland Tampere, Finland France Angers, France Germany Dormagen, Germany India Chennai, India Norway Oslo, Norway Russian Federation Saint Petersburg, Russian Federation Spain Alicante, Spain Sweden Lund, Sweden Less <<
NCT01910441 Type 2 Diabetes Mellitus Phase 4 Terminated(The study was termi... More >>nated due to the unavailability of Continuous Glucose Monitoring sensors (CGMS) which were required to assess the primary end-point.) Less << - -
NCT00106340 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Germany Investigative Centers Nurnberg, Germany Less <<
NCT01910441 - Terminated(The study was termi... More >>nated due to the unavailability of Continuous Glucose Monitoring sensors (CGMS) which were required to assess the primary end-point.) Less << - -
NCT00138580 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Less <<
NCT00138515 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Less <<
NCT03253562 Reducing the Elevated Blood Pr... More >>essure for Diabetic Hypertensive Patients Less << Phase 4 Completed - Egypt ... More >> National institute of diabetes and endocrinology Cairo, Egypt, 11311 Less <<
NCT03088670 Diabetes Mellitus, Type 2 Phase 3 Completed - Russian Federation ... More >> Non-state healthcare Organization "Road Clinical Hospital at the station Chelyabinsk Open Joint Stock Company" Russian Railways Chelyabinsk, Russian Federation, 454048 State Budget Healthcare Institution of Moscow "Endocrinology Dispensary" Moscow, Russian Federation, 119034 SEI HPE "First Moscow State Medical University n.a. I.M. Sechenov of Ministry of Health and Social Development of the Russian Federation", Chair of faculty therapy #2 based at SHI of Moscow "City clinical hospital #61" Moscow, Russian Federation, 119048 State Budget Educational Institution higher professional education "1st Moscow State Medical University n.a. I.M. Sechenov of the Ministry of Healthcare of Russian Federation" Moscow, Russian Federation, 119435 Federal State Institution "Clinical Hospital № 1" of the Office of the President of the Russian Federation Moscow, Russian Federation, 121352 State Budget Healthcare Institution of Moscow city "City Clinical Hospital # 71 by the Department of Healthcare in Moscow" Moscow, Russian Federation, 121374 State Budget Educational Institution of higher professional education "1st Moscow State Medical University n.a. I.M. Sechenov of the Ministry of Healthcare of Russian Federation" based on Endocrinology department of Hospital № 67 n.a L A Vorohobova Moscow, Russian Federation, 123423 SEI APE "Russian Medical Academy of Postgraduate Education of Roszdrav", Chair of endocrinology and diabetology with course of endocrine surgery based at FSI "Central Clinical hospital of civil aviation" Moscow, Russian Federation, 125367 State budgetary institution "Nizhny Novgorod Regional Clinical Hospital n.a Semashko Nizhny Novgorod, Russian Federation, 603126 State Health Care Institution "Perm Regional Hospital for War Veterans" Perm, Russian Federation, 614097 State Educational Institution of Higher Professional Education "Perm State Medical Academy n.a. academician EA Wagner's "Ministry of Health of the Russian Federation on the basis of Department of Endocrinology Regional Clinical Hospital Perm, Russian Federation, 614990 SHI "Republic Hospital n.a. V.A. Baranov" Petrozavodsk, Russian Federation, 185019 State budgetary institution of Ryazan region "City Clinical Hospital № 11" Ryazan, Russian Federation, 390037 St. Petersburg State healthcare institution "City Outpatient Clinic #37" Saint Petersburg, Russian Federation, 191119 FSHI "Clinical Hospital #122 n.a. L.G. Sokolov of FMBA of Russia", Internal medicine department Saint Petersburg, Russian Federation, 194291 State Health Care Institution Leningrad Regional Hospital Saint Petersburg, Russian Federation, 194291 Autonomous Noncommercial Organization "Medical Centre "XXI сentury" Saint Petersburg, Russian Federation, 194354 St. Petersburg State healthcare institution "City Hospital of Saint Martyr Elizaveta" Saint Petersburg, Russian Federation, 195257 FSMEI HPE "Military Medical Academy n.a. S.M. Kirov" of the Ministry of Defence of the Russian Federation, 1st Internal medicine Chair of advanced training Saint Petersburg, Russian Federation, 198013 "Diabetes Center "LLC Samara, Russian Federation, 443041 State Budget Educational Institution higher professional education "Saratov State Medical University n.a. V.I. Razumovsky" of the Ministry of Healthcare of Russian Federation based on Clinical Hospital n.a S.R. Mirotvortsev Saratov, Russian Federation, , 410054 Municipal health care institution "City polyclinic №20 Saratov, Russian Federation, 410018 SBEI HPE "Smolensk State Medical Academy" of the Ministry of Health and Social Development of the Russian Federation, Center of clinical research of diagnostic and medicinal products, Chair of clinical pharmacology Smolensk, Russian Federation, 214019 State budget educational institution of higher education "Smolensk State Medical Academy," of Ministry of Health and Social Development of the Russian Federation on the basis of sanatorium SSMA Smolensk, Russian Federation, 214019 State autonomous healthcare institution of Yaroslavl Region "Сlinical hospital for emergency medical care n. a. N.V. Solovyov" Yaroslavl, Russian Federation, 150003 Municipal clinical health institution Health Service Novo-Yaroslavl Oil Refinery Yaroslavl, Russian Federation, 150023 SHI of Yaroslavl region "Regional Clinical Hospital", Endocrinology department Yaroslavl, Russian Federation, 150062 Less <<
NCT00138606 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Germany Novartis Investigative Site Investigative Centers, Germany Less <<
NCT00414947 Healthy Phase 1 Completed - China ... More >> Novartis Investigative Site Beijing, China Less <<
NCT01862263 Type 2 Diabetes Mellitus Phase 4 Completed - Mexico ... More >> Novartis Investigative Site Mexico, Distrito Federal, Mexico, 06700 Novartis Investigative Site Mexico, Distrito Federal, Mexico, 07300 Novartis Investigative Site Mexico, Distrito Federal, Mexico, 14050 Novartis Investigative Site Metepec, Estado de México, Mexico, 52140 Novartis Investigative Site Celaya, Guanajuato, Mexico, 38000 Novartis Investigative Site Guadalajara, Jalisco, Mexico, 44150 Novartis Investigative Site Guadalajara, Jalisco, Mexico, 44600 Novartis Investigative Site Guadalajara, Jalisco, Mexico, 44670 Novartis Investigative Site Monterrey, Nuevo Leon, Mexico, 64710 Novartis Investigative Site Monterrey, Nuevo León, Mexico, 64020 Novartis Investigative Site Cancun, Quintana Roo, Mexico, 77500 Novartis Investigative Site Culiacán, Sinaloa, Mexico, 80000 Novartis Investigative Site Puebla, Mexico, 72190 Less <<
NCT02176681 Haemodialyzed, Type 2 Diabetes Phase 4 Completed - France ... More >> CH d'Amiens Amiens, France, 80054 CH de Besançon Besancon, France, 25030 AURAL Colmar Colmar, France, 68000 Hospices civils de Colmar Colmar, France, 68024 CH de Dijon Dijon, France, 21079 AURAL Mulhouse Mulhouse, France, 68070 CH de Mulhouse Mulhouse, France, 68070 CH de Nancy Nancy, France, 54000 AURAL Clinique Sainte Anne Strasbourg, France, 67000 Clinique Sainte Anne Strasbourg, France, 67000 Hôpitaux Universitaires de Strasbourg Strasbourg, France, 67091 AURAL Strasbourg Strasbourg, France, 67200 CH de Valenciennes Valenciennes, France, 59300 Less <<
NCT00351884 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Germany Novartis Investigative Site Investigative Centers, Germany Less <<
NCT01565096 Diabetes Mellitus Type II Phase 4 Unknown - Germany ... More >> ikfe GmbH Recruiting Mainz, Germany, 55116 Contact: Thomas Forst, Prof., MD    +49 6131 576 36 16    thomasf@ikfe.de    Contact: Swantje Anders    +49 6131 327 90 22    s.anders@ikfe-cro.de Less <<
NCT00099866 Diabetes Mellitus, Type 2 Phase 3 Completed - Germany ... More >> Novartis investigative Site Investigative Sites, Germany Less <<
NCT00138541 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Less <<
NCT00380380 Diabetes Mellitus, Type 2 PHASE3 COMPLETED 2025-11-06 Munich, 81377, Germany, Munich... More >>, Germany Less <<
NCT01356381 Type 2 Diabetes Mellitus Phase 4 Completed - United Kingdom ... More >> Novartis Investigative Site Newcastle Upon Tyne, United Kingdom, NE4 5PL Less <<
NCT02007278 Type 2 Diabetes ... More >> Hypoglycemia Less << Phase 4 Completed - Colombia ... More >> Novartis Investigative Site Medellín, Antioquia, Colombia Novartis Investigative Site Manizales, Caldas, Colombia, 1700 Novartis Investigative Site Bogotá, Cundinamarca, Colombia Novartis Investigative Site Chía, Cundinamarca, Colombia, 11001000 Novartis Investigative Site Cali, Valle del Cauca, Colombia, 760001 Novartis Investigative Site Bogotá, Colombia, 00000 Novartis Investigative Site Cali, Colombia Novartis Investigative Site Monteria, Colombia Less <<
NCT00616811 Diabetes Mellitus, Type 2 Phase 3 Completed - -
NCT01604213 Type 2 Diabetes Mellitus ... More >> Ischemic Heart Disease Less << Phase 4 Completed - Israel ... More >> Sheba Medical Center, Cardiac Rehabilitation Institute Tel Hashomer, Israel, 52621 Less <<
NCT01649466 Type 2 Diabetes Mellitus Phase 4 Completed - -
NCT02999841 Diabetes Mellitus, Type 2 ... More >> Obesity Less << Phase 4 Unknown January 2018 China, Beijing ... More >> Beijing Pinggu Hospital Recruiting Beijing, Beijing, China, 101200 Contact: Yufeng Li, MD    +86 139 1108 0328       Principal Investigator: Yufeng Li, MD Less <<
NCT00396071 Diabetes Mellitus, Type 2 Phase 3 Completed - Germany ... More >> Diabetes Zentrum Bad Lauterberg Bad Lauterberg, Germany, 37431 Switzerland Novartis Pharmaceuticals Basel, Switzerland Less <<
NCT00765830 Diabetes Mellitus, Type 2 ... More >> Renal Insufficiency Less << Phase 3 Completed - -
NCT00567047 Type-2 Diabetes Phase 1 Completed - United States, Florida ... More >> Novartis Investigator Site Miami, Florida, United States, 33136 Novartis Investigator Site Orlando, Florida, United States, 32809 United States, Minnesota Novartis Investigator Site Minneapolis, Minnesota, United States, 55404 United States, Tennessee Novartis Investigator Site Knoxville, Tennessee, United States, 37920 United States, Virginia Novartis Investigator Site Richmond, Virginia, United States, 23298 Germany Novartis Investigator Site Kiel, Germany Less <<
NCT00101712 Diabetes Mellitus, Type 2 Phase 3 Completed - Germany ... More >> Novartis Investigative Site Investigative Site, Germany Switzerland Novartis Investigative Site Basel, Switzerland Less <<
NCT02007278 - Completed - -
NCT00099853 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Less <<
NCT00138554 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Less <<
NCT00818571 Renal Impairment ... More >> Diabetes Less << Phase 1 Phase 2 Completed - Russian Federation ... More >> Novartis Investigator Site Moscow, Russian Federation Less <<
NCT02343926 Type 2 Diabetes Mellitus Phase 3 Completed - Russian Federation ... More >> Investigational Site 03 Vladimir, Vladimirskaya Oblast, Russian Federation, 600023 Less <<
NCT01357252 Type 2 Diabetes Mellitus Phase 3 Completed - China, Beijing ... More >> Novartis Investigative Site Beijing, Beijing, China, 100088 China, Hebei Novartis Investigative Site Shijiazhuang, Hebei, China, 050051 China, Hubei Novartis Investigative Site Wuhan, Hubei, China, 430070 China, Hunan Novartis Investigative Site Changsha, Hunan, China, 410003 China, Jiangsu Novartis Investigative Site Nanjing, Jiangsu, China, 210006 Novartis Investigative Site Nanjing, Jiangsu, China, 210008 Novartis Investigative Site Nanjing, Jiangsu, China, 210029 Novartis Investigative Site Zhenjiang, Jiangsu, China, 212001 China, Liaoning Novartis Investigative Site ShenYang, Liaoning, China, 110003 China, Shanghai Novartis Investigative Site Shanghai, Shanghai, China China, Tianjin Novartis Investigative Site Tianjin, Tianjin, China, 300211 China Novartis Investigative Site Beijing, China, 100029 Novartis Investigative Site Beijing, China, 100034 Novartis Investigative Site Beijing, China, 100730 Novartis Investigative Site Beijing, China Novartis Investigative Site Guang zhou, China, 510080 Novartis Investigative Site Shanghai, China, 200040 Novartis Investigative Site Shanghai, China, 200233 Less <<
NCT01159249 Type 2 Diabetes PHASE3 COMPLETED 2025-01-12 Novartis Investigative Site, H... More >>unabashi, Chiba, 274-0805, Japan|Novartis Investigative Site, Chikushino, Fukuoka, 818-0036, Japan|Novartis Investigative Site, Itoshima-shi, Fukuoka, 819-1102, Japan|Novartis Investigative Site, Koriyama, Fukushima, 963-8851, Japan|Novartis Investigative Site, Kobe, Hyogo, 658-0064, Japan|Novartis Investigative Site, Kawasaki, Kanagawa, 210-0852, Japan|Novartis Investigative Site, Kawasaki, Kanagawa, 212-0024, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, 221-0077, Japan|Novartis Investigative Site, Yokohama, Kanagawa, 221-0065, Japan|Novartis Investigative Site, Izumisano, Osaka, 598-0048, Japan|Novartis Investigative Site, Hannou, Saitama, 357-0024, Japan|Novartis Investigative Site, Hiki-Gun, Saitama, 355-0328, Japan|Novartis Investigative Site, Kawaguchi, Saitama, 332-0012, Japan|Novartis Investigative Site, Koshigaya city, Saitama, 343-0826, Japan|Novartis Investigative Site, Tokorozawa, Saitama, 359-1161, Japan|Novartis Investigative Site, Edogawa-ku, Tokyo, 134-0084, Japan|Novartis Investigative Site, Hachioji, Tokyo, 192-0046, Japan|Novartis Investigative Site, Katsushika-ku, Tokyo, 125-0041, Japan|Novartis Investigative Site, Minato-ku, Tokyo, 108-0075, Japan|Novartis Investigative Site, Shinagawa-ku, Tokyo, 141-0032, Japan|Novartis Investigative Site, Toshima-ku, Tokyo, 171-0021, Japan|Novartis Investigative Site, Fukuoka, 807-0857, Japan|Novartis Investigative Site, Fukuoka, 816-0094, Japan|Novartis Investigative Site, Fukuoka, 819-0168, Japan Less <<
NCT01679899 Type 2 Diabetes Mellitus ... More >> Menopause Osteoporosis Osteopenia Less << Phase 4 Completed - Brazil ... More >> Centro de Diabetes Curitiba Curitiba, Parana, Brazil, 80810040 Less <<
NCT01703637 Type 2 Diabetes Mellitus Not Applicable Unknown - China, Shandong ... More >> YuCheng people's hospital Recruiting Dezhou, Shandong, China, 253000 Contact: Pengfei Li       lpf9669@163.com    Hospital of SINOTRUK Recruiting Jinan, Shandong, China, 250010 Contact: Xiling Fu       fxl1936@163.com    Jinan central hospital Recruiting Jinan, Shandong, China, 250010 Contact: Shuguang Pang       shuguangpang@163.com    The jinan military region general hospital Recruiting Jinan, Shandong, China, 250010 Contact: Zhaoshun Jiang       zhaoshunjiang@sohu.com    Qianfoshan Hospital Recruiting Jinan, Shandong, China, 250012 Contact: Lin Liao, MD    8615168888260    liaolin@medmail.com.cn    People's Hospital of Qingdao Chengyang Recruiting Qingdao, Shandong, China, 266100 Contact: Xiaopang Rao       123raoxiaopang@163.com    Zibo central hospital Recruiting Zibo, Shandong, China, 255000 Contact: Xiaodong Zhao       19xiaodong@163.com    Zibo eighth people's hospital Recruiting Zibo, Shandong, China, 255000 Contact: Ling Dai    +86 13853388549 Less <<
NCT01404676 Type 2 Diabetes Mellitus Phase 4 Completed - Korea, Republic of ... More >> Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul, Korea, Republic of, 135-710 Less <<
NCT01000688 Type 2 Diabetes ... More >> Endothelial Dysfunction Less << Phase 3 Completed - Netherlands ... More >> Radboud University Nijmegen Medical Centre Nijmegen, Netherlands, 6500 HB Less <<
NCT01196546 Type 2 Diabetes Mellitus Phase 4 Completed - Thailand ... More >> BMA Medical College and Vajira Hospital Bangkok, Thailand King Chulalongkorn Memorial Hospital Bangkok, Thailand Phamongkutklao Hospital Bangkok, Thailand Police General Hospital Bangkok, Thailand Siriraj Hospital Bangkok, Thailand Khon Kaen Hospital Khon Kaen, Thailand Fort Suranaree Hospital Nakhon Ratchasima, Thailand Maharat Nakhon Ratchasima Hospital Nakhon Ratchasima, Thailand Less <<
NCT01262586 Type II Diabetes Mellitus Phase 3 Completed - Germany ... More >> Novartis Investigative Site Mainz, Germany Less <<
NCT00380445 Diabetes Mellitus, Type 2 PHASE3 COMPLETED 2025-04-07 Novartis Pharmaceuticals, East... More >> Hanover, New Jersey, 07936, United States|Novartis Investigative Site, Investigative Centers, Germany Less <<
NCT01871558 Type 2 Diabetes Mellitus (T2DM... More >>) Less << Phase 3 Completed - France ... More >> Novartis Investigative Site Antibes, France, 06600 Novartis Investigative Site Auxerre, France, 89000 Novartis Investigative Site Bar le Duc, France, 55012 Novartis Investigative Site Bondy, France, 93143 Novartis Investigative Site Brest, France, 29200 Novartis Investigative Site Caen, France, 14000 Novartis Investigative Site Corbeil Essonnes, France, 91100 Novartis Investigative Site Fleury sur Orne, France, 14123 Novartis Investigative Site Maisons Laffitte, France, 78600 Novartis Investigative Site Menton, France, 06500 Novartis Investigative Site Montpellier, France, 34090 Novartis Investigative Site Paris, France, 75010 Novartis Investigative Site Rennes, France, 35203 Novartis Investigative Site Saint Nazaire, France, 44600 Novartis Investigative Site Sanary Sur Mer, France, 83110 Novartis Investigative Site Strsbourg, France, 67000 Novartis Investigative Site Toulouse, France, 31300 Novartis Investigative Site Valence, France, 26000 Novartis Investigative Site Valenciennes, France, 59300 Less <<
NCT03563794 T2DM Phase 4 Recruiting December 10, 2019 China, Fujian ... More >> The first afilliated hospital of Xiamen university Recruiting Xiamen, Fujian, China, 361003 Contact: Xue-jun Li, MD,PHD    13860451316    lixuejue99@yahoo.com.cn    Principal Investigator: Xue-jun Li, MD,PhD Less <<
NCT03693560 Coronary Artery Disease ... More >> Diabetes Mellitus, Type 2 Less << Phase 4 Active, not recruiting February 2019 Egypt ... More >> Faculty of Pharmacy - Damanhour University. Damanhūr, Egypt Less <<
NCT00894868 Congestive Heart Failure ... More >> Type II Diabetes Mellitus Less << Phase 4 Completed - -
NCT01233622 Type 2 Diabetes Mellitus Phase 3 Completed - -
NCT02002221 Type 2 Diabetes Mellitus (T2DM... More >>) Less << Phase 4 Completed - Japan ... More >> Novartis Investigative Site Fukuoka-city, Fukuoka, Japan, 810-8798 Novartis Investigative Site Fukuoka-city, Fukuoka, Japan, 815-0071 Novartis Investigative Site Fukutsu-city, Fukuoka, Japan, 811-3217 Novartis Investigative Site Kitakyushu-city, Fukuoka, Japan, 800-0295 Novartis Investigative Site Koriyama-city, Fukushima, Japan, 963-8851 Novartis Investigative Site Mito-city, Ibaraki, Japan, 311-4153 Novartis Investigative Site Ibusuki-city, Kagoshima, Japan, 891-0401 Novartis Investigative Site Yokohama-city, Kanagawa, Japan, 221-0802 Novartis Investigative Site Kumamoto-city, Kumamoto, Japan, 861-8039 Novartis Investigative Site Kumamoto-city, Kumamoto, Japan, 861-8520 Novartis Investigative Site Yatsushiro-city, Kumamoto, Japan, 866-8533 Novartis Investigative Site Kyoto-city, Kyoto, Japan, 615-0035 Novartis Investigative Site Sendai-city, Miyagi, Japan, 980-0021 Novartis Investigative Site Hirakata-City, Osaka, Japan, 573-0153 Novartis Investigative Site Izumisano-city, Osaka, Japan, 598-8577 Novartis Investigative Site Osaka-city, Osaka, Japan, 530-0001 Novartis Investigative Site Osaka-city, Osaka, Japan, 534-0021 Novartis Investigative Site Takatsuki-city, Osaka, Japan, 569-1096 Novartis Investigative Site Ageo-city, Saitama, Japan, 362-8588 Novartis Investigative Site Saitama-city, Saitama, Japan, 336-0963 Novartis Investigative Site Sayama-city, Saitama, Japan, 350-1305 Novartis Investigative Site Tokorozawa-city, Saitama, Japan, 359-1161 Novartis Investigative Site Adachi-ku, Tokyo, Japan, 123-0845 Novartis Investigative Site Chiyoda-ku, Tokyo, Japan, 101-0024 Novartis Investigative Site Chuo-ku, Tokyo, Japan, 103-0027 Novartis Investigative Site Chuo-ku, Tokyo, Japan, 103-0028 Novartis Investigative Site Chuo-ku, Tokyo, Japan, 104-0061 Novartis Investigative Site Nerima-ku, Tokyo, Japan, 177-0041 Novartis Investigative Site Nerima-ku, Tokyo, Japan, 177-0051 Novartis Investigative Site Ota-ku, Tokyo, Japan, 144-0051 Novartis Investigative Site Suginami-ku, Tokyo, Japan, 166-0004 Less <<
NCT02002221 - Completed - -
NCT01963130 - Completed - Turkey ... More >> Bezmialem VU Istanbul, Turkey, 34093 Less <<
NCT01871558 - Completed - -
NCT01099137 Diabetes Phase 4 Completed - Korea, Republic of ... More >> Seoul National University Bundang Hospital Seongnam, Korea, Republic of Less <<
NCT00633997 Diabetes Mellitus, Type 2 Phase 1 Phase 2 Terminated(After analysis of t... More >>he existing data, it was determined that additional skin biopsy samples would not be required to determine study outcome.) Less << - United States, Maryland ... More >> Novartis Investigator Site Baltimore, Maryland, United States, 21225 Less <<
NCT00936234 SDF-1 is an Important Cytokine... More >> for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors Less << PHASE2|PHASE3 WITHDRAWN 2025-05-13 Department of Cardiology, Fran... More >>kfurt, 60590, Germany Less <<
NCT02849899 Disorder Related to Renal Tran... More >>splantation Diabetes Less << Phase 3 Not yet recruiting January 2020 -
NCT01766778 - Completed - -
NCT01758380 Type 2 Diabetes Mellitus Phase 4 Completed - -
NCT01766778 Type-2 Diabetes Mellitus Phase 4 Completed - Hong Kong ... More >> Novartis Investigative Site Hong Kong SAR, Hong Kong Novartis Investigative Site HongKong, Hong Kong Novartis Investigative Site Tuen Mun, Hong Kong Less <<
NCT01528254 Type 2 Diabetes Mellitus Phase 4 Active, not recruiting April 18, 2019 -
NCT01559025 Type 1 Diabetes|Insulin Depend... More >>ent Diabetes|Juvenile Onset Diabetes Mellitus|Autoimmune Diabetes Less << PHASE3 UNKNOWN 2025-03-17 Federal University of S?o Paul... More >>o, S?o Paulo, 04022-001, Brazil Less <<
NCT00980356 Diabetes Mellitus PHASE2 COMPLETED 2025-12-12 Medical University of Vienna, ... More >>Vienna, 1090, Austria Less <<
NCT03500900 Healthy Not Applicable Completed - -
NCT01822548 Type 2 Diabetes Phase 3 Completed - Italy ... More >> Azienda Opedaliera-Universitaria Parma, Italy, 43126 Azienda Ospedaliera-Universitaria Parma, Italy, 43126 Less <<
NCT01257451 Type 2 Diabetes Mellitus Phase 3 Completed - -
NCT01822548 - Completed - -
NCT02853630 TYpe 2 Diabetes Mellitus Phase 4 Active, not recruiting December 2018 India ... More >> Jnana Sanjeevini Medical Centre Bangalore, Karnataka, India, 560 078 Vikas Pai Research Foundation Pune, Maharashtra, India, 411 005 Singhvi Health Centre Chennai, Tamil Nadu, India, 600 019 Dr V.Seshiah Diabetes research Institute, Dr V.Balaji Diabetes care centre Chennai, Tamil Nadu, India, 600029 Arthur Asirvatham Hospital Madurai, Tamil Nadu, India, 625 020 Ramana Maharishi Rangammal Hospital Tiruvannamalai, Tamil Nadu, India, 606 603 Less <<
NCT01147276 Diabetes|Hypoglycemia PHASE4 COMPLETED 2025-12-11 Department of Clinical Science... More >>s Lund, Lund University, Lund, 221 84, Sweden Less <<
NCT01398592 Diabetes Mellitus Type 2 Phase 4 Completed - Germany ... More >> Novartis Investigative Site Bad Oeynhausen, Germany, 32549 Novartis Investigative Site Berlin, Germany, 12347 Novartis Investigative Site Berlin, Germany, 13597 Novartis Investigative Site Berlin, Germany, 14089 Novartis Investigative Site Celle, Germany, 29221 Novartis Investigative Site Hannover, Germany, 30165 Novartis Investigative Site Hannover, Germany, 30167 Novartis Investigative Site Kassel, Germany, 34117 Novartis Investigative Site Kirchhain, Germany, 35274 Novartis Investigative Site Lehrte, Germany, 31275 Novartis Investigative Site Mülheim, Germany, 45468 Novartis Investigative Site Oberhausen, Germany, 46049 Novartis Investigative Site Osnabrück, Germany, 49080 Novartis Investigative Site Potsdam, Germany, 14469 Novartis Investigative Site Stuttgart, Germany, 70378 Less <<
NCT01219400 Diabetes PHASE4 COMPLETED 2025-12-13 Lund University, Lund, 22184, ... More >>Sweden Less <<
NCT02816970 Healthy Phase 1 Completed - Egypt ... More >> Genuine Research Center GRC Cairo, Egypt, 11757 Less <<
NCT01582230 Type 2 Diabetes Mellitus Phase 3 Completed - China, Beijing ... More >> Novartis Investigative Site Beijing, Beijing, China, 100730 China, Hunan Novartis Investigative Site Changsha City, Hunan, China, 410011 Novartis Investigative Site Changsha, Hunan, China, 410003 China, Jiangsu Novartis Investigative Site Nanjing, Jiangsu, China, 210006 Novartis Investigative Site Wu Xi, Jiangsu, China, 214023 China, Jiangxi Novartis Investigative Site Nanchang, Jiangxi, China, 330006 China, Liaoning Novartis Investigative Site Shenyang, Liaoning, China, 110003 China, Shandong Novartis Investigative Site Jinan, Shandong, China, 250031 China, Shanxi Novartis Investigative Site Xi'an, Shanxi, China, 710032 China, Sichuan Novartis Investigative Site Chengdu, Sichuan, China, 610072 China Novartis Investigative Site Beijing, China Novartis Investigative Site Shanghai, China, 200025 Novartis Investigative Site Tianjin, China, 300052 Philippines Novartis Investigative Site Metro Manila, Philippines, 1500 Novartis Investigative Site Pasay City, Philippines, 1300 Novartis Investigative Site Quezon City, Philippines, 1102 Singapore Novartis Investigative Site Singapore, Singapore, 169608 Novartis Investigative Site Singapore, Singapore, 768825 Thailand Novartis Investigative Site Bangkok, Thailand, 10330 Novartis Investigative Site Bangkok, Thailand, 10400 Novartis Investigative Site Khon Kaen, Thailand, 40002 Less <<
NCT02475070 Type 2 Diabetes Phase 4 Completed - Sweden ... More >> Lund University Lund, Sweden, 22184 Less <<
NCT02145611 Type 2 Diabetes Mellitus ... More >> Hypertension Endothelial Dysfunction Less << Phase 4 Completed - Brazil ... More >> Fundação Faculdade Regional de Medicina de São José do Rio Preto São José do Rio Preto, São Paulo, Brazil, 15090-000 Less <<
NCT01827280 1- Microvascular Function|2-ox... More >>idative Stress|3-inflammation Less << PHASE4 COMPLETED 2025-11-16 Laboratory for Clinical and Ex... More >>perimental Research on Vascular Biology, Rio de Janeiro, 20550-900, Brazil Less <<
NCT01426802 Type 2 Diabetes Mellitus Phase 4 Completed - Egypt ... More >> Investigative site Cairo, Egypt Less <<
NCT01582243 Diabetes Mellitus, Type 2 PHASE4 COMPLETED 2025-09-15 Novartis Investigative Site, C... More >>hanghua, 500, Taiwan Less <<
NCT01497522 Diabetes Mellitus, Type 2 Phase 3 Completed - Japan ... More >> Novartis Investigative Site Kitakyushu, Fukuoka, Japan, 800-0296 Novartis Investigative Site Kurume, Fukuoka, Japan, 830-8543 Novartis Investigative Site Ohkawa-city, Fukuoka, Japan, 831-0016 Novartis Investigative Site Kawasaki-city, Kanagawa, Japan, 210-0014 Novartis Investigative Site Yokohama, Kanagawa, Japan, 221-0802 Novartis Investigative Site Kyoto-city, Kyoto, Japan, 615-0035 Novartis Investigative Site Takatsuki, Osaka, Japan, 569-1096 Novartis Investigative Site Ageo-city, Saitama, Japan, 362-8588 Novartis Investigative Site Bunkyo-ku, Tokyo, Japan, 113-0031 Novartis Investigative Site Edogawa-ku, Tokyo, Japan, 134-0084 Novartis Investigative Site Hachioji, Tokyo, Japan, 192-0046 Novartis Investigative Site Kiyose, Tokyo, Japan, 204-0021 Novartis Investigative Site Minato-ku, Tokyo, Japan, 105-7390 Novartis Investigative Site Minato-ku, Tokyo, Japan, 108-0075 Novartis Investigative Site Nerima-ku, Tokyo, Japan, 177-0051 Novartis Investigative Site Shinagawa-ku, Tokyo, Japan, 141-0032 Novartis Investigative Site Toshima-ku, Tokyo, Japan, 171-0021 Novartis Investigative Site Fukuoka, Japan, 810-0001 Novartis Investigative Site Fukuoka, Japan, 819-0168 Novartis Investigative Site Kyoto, Japan, 607-8062 Less <<
NCT01541956 Type 2 Diabetes Phase 4 Completed - China ... More >> Novartis Investigative Site Beijing, China, 100028 Less <<
NCT01686932 - Completed - -
NCT01686932 Diabetes Mellitus Type 2 Phase 4 Completed - Germany ... More >> Novartis Investigative Site Berlin, Germany, 10115 Novartis Investigative Site Berlin, Germany, 13055 Novartis Investigative Site Dortmund, Germany, 44137 Novartis Investigative Site Dresden, Germany, 01307 Novartis Investigative Site Elsterwerda, Germany, 04910 Novartis Investigative Site Falkensee, Germany, 14612 Novartis Investigative Site Magdeburg, Germany, 39112 Novartis Investigative Site Neuss, Germany, 41460 Novartis Investigative Site Potsdam, Germany, 14469 Novartis Investigative Site Sulzbach-Rosenberg, Germany, 92237 Novartis Investigative Site Wallerfing, Germany, 94574 Less <<
NCT03577184 - Not yet recruiting March 2019 -
NCT01882907 Type 2 Diabetes Phase 4 Completed - Korea, Republic of ... More >> Busan Saint Mary's Medical Center Busan, Korea, Republic of Dong-AUniversity Medical Center Busan, Korea, Republic of Inje University Baik Hospital Busan, Korea, Republic of Kosin University Hospital Busan, Korea, Republic of Pusan National University Hospital Busan, Korea, Republic of Changwon Fatima Hospital Changwon, Korea, Republic of Daegu Catholic University Medical Center Daegu, Korea, Republic of Keimyung University Dongsan Medical Center Daegu, Korea, Republic of Kyungbuk National Universtiy Hospital Daegu, Korea, Republic of Chonnam National University Hospital Gwangju, Korea, Republic of Chosun University Hospital Gwangju, Korea, Republic of Chonbuk National University Hospital Jeonju, Korea, Republic of Gyeongsang National University Hospital Jinju, Korea, Republic of Masan Samsung Medical Center Masan, Korea, Republic of Ulsan University Hospital Ulsan, Korea, Republic of Less <<
NCT01882907 - Completed - -
NCT01582243 Diabetes Mellitus, Type 2 PHASE4 COMPLETED 2025-09-15 Novartis Investigative Site, C... More >>hanghua, 500, Taiwan Less <<
NCT00312130 Pre-diabetes PHASE3 COMPLETED 2025-11-06 University of Washington, Seat... More >>tle, Washington, 98108, United States Less <<
NCT00351585 Diabetes Mellitus, Type 2 PHASE3 COMPLETED 2025-09-05 -
NCT01426737 Type 2 Diabetes PHASE4 UNKNOWN 2025-01-13 Universitiy Hospital, Zurich, ... More >>Switzerland Less <<
NCT00325117 Diabetes Mellitus, Type 2 PHASE3 COMPLETED - Novartis Pharmaceuticals, Toky... More >>o, Japan Less <<
NCT00300287 Diabetes Mellitus, Type 2 PHASE3 COMPLETED 2007-06-26 Investigative Sites, Germany
NCT00389415 Diabetes Mellitus, Type 2 PHASE3 COMPLETED - Novartis Pharmaceuticals, Toky... More >>o, Japan Less <<
NCT00368134 Diabetes Mellitus, Type 2 PHASE3 COMPLETED - Novartis Pharmaceuticals, Toky... More >>o, Japan Less <<
NCT04654676 Diabetes Mellitus, Type 2 PHASE4 COMPLETED 2019-08-31 Sarawak General Hospital, Kuch... More >>ing, Malaysia Less <<
NCT00390520 Diabetes Mellitus, Type 2 PHASE3 COMPLETED 2025-09-07 Novartis, Basel, Switzerland
NCT00351546 Diabetes Mellitus, Type 2 PHASE3 COMPLETED 2025-12-05 -
NCT01452113 Diabetes Mellitus PHASE2 COMPLETED 2025-03-13 UH Toulouse, Toulouse, 31059, ... More >>France Less <<
NCT05429554 Type 2 Diabetes Mellitus UNKNOWN 2025-09-22 National Institute of diabetes... More >> and endocrinology, Cairo, Al Kasr Al Aini, Egypt Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.30mL

0.66mL

0.33mL

16.48mL

3.30mL

1.65mL

32.96mL

6.59mL

3.30mL

References

 

Historical Records

Categories